The European pharmaceutical agency is evaluating the possibility of extending the use of Moderna to the over 12s
Rome – It’s not over, the guard must still be kept very high. And the enemy to be defeated I am the variants. The new warning from the World Health Organization is not taken for granted: the concrete risk feared by scientists is that new, even more dangerous variants will arise. An alert that increases concerns, while infections are rising throughout Europe and in Italy, the Gimbe Foundation highlights how over 2 million over-60s are still not vaccinated and therefore are at risk.
✉ COVID IN LIGURIA: SUBSCRIBE TO THE NEW NEWSLETTER
At the same time Ema, the European Medicines Agency confirms the effectiveness of available vaccines also against variants and adds: soon a second immunizer could be available for children over-12. The data and considerations come from the usual briefing from Geneva on the pandemic situation: the WHO emergency committee has warned that new variants of the SarsCoV2 virus could spread around the world making it even more difficult to stop the epidemic.
“It’s not over at all,” said the experts, underlining the strong likelihood that new and perhaps more dangerous variants will emerge that could be even more difficult to control. Currently, however, the EMA reassures, a full course of the four available Covid vaccines still provides high protection against all variants in circulation, including the Delta, especially against serious illness and hospitalization.
A further confirmation also comes from the publication on New England Journal of Medicine data confirming the efficacy of the single-dose J&J vaccine against Delta and the duration of the immune response for at least 8 months. In the face of effective vaccines, it is therefore extremely important to immunize as many people as possible in Europe.
The EU Agency is also evaluating the request to extend the use of Moderna’s Spikevax vaccine to young people between 12 and 17 years old – currently vaccinable only with the Pfizer immunizer – and a decision is expected at the end of next week. As for a possible third dose, “it is now too early to confirm if and when a booster dose will be needed, because there is not yet enough data from vaccination campaigns and ongoing studies to understand how long the vaccine will last”, he said. clarified the Ema head of vaccine strategy Marco Cavaleri.